Physicians' Academy for Cardiovascular Education

A clinical view on BET inhibition in targeting residual risk in CVD and diabetes

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Kausik Ray, MD - London, UK

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

Landmark trials with PCSK9 inhibitors

10' education - Dec. 11, 2018 - Ph. Gabriel Steg, MD - Paris, France

Moving to benefit-based medicine with a lifetime risk model

10' education - Dec. 10, 2018 - ESC 2018 - Munich, Germany - Prof. Frank Visseren - Utrecht, The Netherlands

Translating GLP-1RA trial outcomes to cardiology practice: Which patients will benefit?

10' education - Dec. 10, 2018 - Prof. Lars Rydén, MD - Stockholm Sweden

PCSK9 inhibitors: How do they work?

10' education - Dec. 4, 2018 - John Chapman - Paris, France

Long term benefits of antihypertensive and cholesterol-lowering treatment in hypertension

10' education - Nov. 20, 2018 - Dr. Ajay Gupta - London, UK

Lp(a) lowering with PCSK9 inhibitor not enough to tackle artery wall inflammation

3' education - Dec. 3, 2018 - Prof. Erik Stroes, MD

Screening for high blood pressure globally

10' education - Nov. 20, 2018 - Dr. Thomas Beaney - London, Uk

Current and future clinical approaches to manage HFpEF

10' education - Aug. 27, 2018 - Burkert Pieske, MD - Berlin, Germany

GLP-1 receptor agonists: The cardiovascular benefits beyond glucose control

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Filip K. Knop - Copenhagen, Denmark

Unexpectedly large CV benefit with icosapent ethyl in statin-treated patients at high CV risk

3' education - Nov. 20, 2018 - Prof. Erik Stroes, MD

Lowering Lp(a) potently and safely with antisense technology

3' education - Nov. 20, 2018 - Sotirios Tsimikas, MD

Physical activity: every step counts, for everybody

3' education - Nov. 20, 2018 - Admiral Brett Giroir, MD - Washington, DC, USA

Vitamin D and omega-3 supplements did not meet primary cancer and CV endpoints in primary prevention cohort

3' education - Nov. 15, 2018 - JoAnn Manson, MD

Practice-changing results on in-hospital treatment of acute decompensated HF

3' education - Nov. 15, 2018 - Larry Allen, MD

Yoga-based cardiac rehabilitation program improves quality of life in post-MI patients

3' education - Nov. 15, 2018 - Dorairaj Prabhakaran, MD

Not all fish oils are created equal: different compounds have different effects

3' education - Nov. 13, 2018 - Deepak Bhatt, MD - Boston, MA, VS.

Initiation of ARNI in patients with acute decompensated heart failure

3' education - Nov. 13, 2018 - Eric Velazquez, MD

Comprehensive US approach to stimulate physical activity should tackle obesity and improve health

3' education - Nov. 13, 2018 - Dr. Ivor Benjamin - Milwaukee, WS, USA

A clinical view on BET inhibition in targeting residual risk in CVD and diabetes

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Kausik Ray, MD - London, UK
BET proteins can stimulate inflammatory processes by regulating genes. Prof. Kausik Ray discusses the role of BET inhibition in reducing CVD risk in patients with diabetes.

BET proteins can stimulate inflammatory processes by regulating genes. Prof. Kausik Ray discusses the role of BET inhibition in reducing CVD risk in patients with diabetes.

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands
Currently only small numbers of ASCVD patients achieve target LDL-c levels due to certain issues surrounding lipid lowering therapy. Prof. John Kastelein discusses the role of PCSK9 inhibition and future perspectives on lipid lowering.

Currently only small numbers of ASCVD patients achieve target LDL-c levels due to certain issues surrounding lipid lowering therapy. Prof. John Kastelein discusses the role of PCSK9 inhibition and future perspectives on lipid lowering.

PCSK9-targeted siRNA therapy: effective, safe and durable lipid-lowering irrespective of diabetes status

Literature - Dec. 11, 2018 - Leiter LA et al. - Diabetes Care 2018
A post-hoc analysis showed reduced LDL-c levels and improved lipid profiles up to 180 days with one or two doses of inclisiran on top of standard care in the presence and absence of diabetes, compared to placebo.

A post-hoc analysis showed reduced LDL-c levels and improved lipid profiles up to 180 days with one or two doses of inclisiran on top of standard care in the presence and absence of diabetes, compared to placebo.

Landmark trials with PCSK9 inhibitors

PCSK9: Outcomes and trials in clinical perspective

10' education - Dec. 11, 2018 - Ph. Gabriel Steg, MD - Paris, France
Prof. Steg summarizes the main results from recent clinical trials with PCSK9 inhibitors and presents some additional analyses in subgroups.

PCSK9: Outcomes and trials in clinical perspective Prof. Steg summarizes the main results from recent clinical trials with PCSK9 inhibitors and presents some additional analyses in subgroups.

Elevated BP before the age of 40 years associated with incident CVD events in middle age

Literature - Dec. 10, 2018 - Yano Y et al., - JAMA. 2018

Community-based data show that increasing categories of severity of hypertension according to the 2017 ACC/AHA BP Guidelines are associated with increasing risk of CVD events in middle age.

Type of existing CVD at baseline affects CV benefits of SGLT2 inhibition

Literature - Dec. 10, 2018 - Zelniker TA et al. - The Lancet 2018
A meta-analysis of three CVOTs showed moderate benefits of SGLT2i on atherosclerotic MACE only in those with ASCVD, whereas robust benefits on HHF and renal disease were observed regardless of baseline CVD or HF.

A meta-analysis of three CVOTs showed moderate benefits of SGLT2i on atherosclerotic MACE only in those with ASCVD, whereas robust benefits on HHF and renal disease were observed regardless of baseline CVD or HF.

Moving to benefit-based medicine with a lifetime risk model

10' education - Dec. 10, 2018 - ESC 2018 - Munich, Germany - Prof. Frank Visseren - Utrecht, The Netherlands
Current CV risk scores overestimate risk in elderly and underestimate risk in young subjects. Prof. Frank Visseren emphasizes the need of CV lifetime risk prediction and presents the U-prevent calculator that estimates gain in CVD-free life based on lifetime CV risk and treatment effects in individuals.

Current CV risk scores overestimate risk in elderly and underestimate risk in young subjects. Prof. Frank Visseren emphasizes the need of CV lifetime risk prediction and presents the U-prevent calculator that estimates gain in CVD-free life based on lifetime CV risk and treatment effects in individuals.

Translating GLP-1RA trial outcomes to cardiology practice: Which patients will benefit?

10' education - Dec. 10, 2018 - Prof. Lars Rydén, MD - Stockholm Sweden
Different GLP-1RAs have shown different effects in CV outcomes trials. Prof Rydén scrutinizes the results of the trials to learn more about the effects of individual GLP-1RAs and what the differences may originate from.

Different GLP-1RAs have shown different effects in CV outcomes trials. Prof Rydén scrutinizes the results of the trials to learn more about the effects of individual GLP-1RAs and what the differences may originate from.

DOAC treatment safe and effective in AF despite multi-morbidity

Literature - Dec. 4, 2018 - Alexander KP et al. - American Heart Journal 2018

A post-hoc analysis of the ARISTOTLE trial showed safety and efficacy of apixaban compared to warfarin in AF patients aged 55 years or older with multi-morbidity.

ACC Expert Consensus Decision Pathway gives recommendations on use of novel anti-diabetes drugs

News - Dec. 4, 2018

Expert Consensus Decision Pathways are meant to complement guidelines and bridge remaining gaps in clinical guidance, in this case the use of SGLT2 inhibitors and GLP-1RAs to lower CV risk in T2DM.

Contribute to the 87th EAS congress: deadline abstract submission postponed

Dec. 4, 2018

The deadline for abstract submission for the 87th edition of the European Society of Atherosclerosis congress, held in Maastricht, The Netherlands, on May 26 - 29, 2019, has been postponed to December 11, 2018.

PCSK9 inhibitors: How do they work?

PCSK9: Outcomes and trials in clinical perspective

10' education - Dec. 4, 2018 - John Chapman - Paris, France
Prof. Chapman explains the biology of PCSK9, its role in the regulation of LDL-R expression and the impact of a therapeutic approach with PCSK9 inhibitors.

PCSK9: Outcomes and trials in clinical perspective Prof. Chapman explains the biology of PCSK9, its role in the regulation of LDL-R expression and the impact of a therapeutic approach with PCSK9 inhibitors.